Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer


This study is an open, multicenter, randomized controlled clinical trial for patients with newly diagnosed primary invasive breast cancer and clinical stage of T2 or above. The main purpose of this study is to evaluate the efficacy of dose-dense nab-paclitaxel compared with dose-dense docetaxel followed by anthracycline and cyclophosphamide in the treatment of HR positive and HER-2 negative breast cancer. The effectiveness and safety of the treatment.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 21, 2021


  • Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide
    • nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
  • Drug: Docetaxel followed by anthracycline and cyclophosphamide
    • Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide

Arms, Groups and Cohorts

  • Experimental: nab-paclitaxel
  • Active Comparator: Docetaxel

Clinical Trial Outcome Measures

Primary Measures

  • RCB
    • Time Frame: 2 years
    • Residual tumor load

Secondary Measures

  • pCR
    • Time Frame: 2 years
    • Complete remission of Pathology

Participating in This Clinical Trial

Inclusion Criteria

  • 1) age: 18-70 years old, female;

2) patients with primary breast cancer, T2 or above, diagnosed by histopathology;

3) HR was positive and HER-2 was negative by IHC;

4) according to the RECIST 1.1 standard, there should be at least one measurable objective focus with tumor diameter > 2cm;

5) ECoG physical fitness score 0-1;

6) LVEF≥55%;

7) bone marrow function: neutrophil ≥ 1.5 × 109 / L, platelet ≥ 100 × 109 / L, hemoglobin ≥ 90g / L;

8) liver and kidney function: serum creatinine ≤ 1.5 times the upper limit of normal value; AST and alt ≤ 2.5 times the upper limit of normal value; total bilirubin ≤ 1.5 times the upper limit of normal value, or patients with Gilbert's syndrome ≤ 2.5 times the upper limit of normal value;

9) patients have good compliance with the planned treatment, can understand the research process of this study and sign the written informed consent

Exclusion Criteria

  • 1) previously received cytotoxic chemotherapy, endocrine therapy, biological therapy or radiotherapy for any reason;

2) patients with stage IV metastasis at the initial diagnosis;

2) New York Heart Association (NYHA) rating of patients with heart disease above grade II (including grade II);

3) patients with serious systemic infection or other serious diseases;

4) patients who are known to be allergic or intolerant to chemotherapy drugs or their adjuvants;

5) in the past 5 years, there have been other malignant tumors, except the cured carcinoma in situ of cervix and skin cancer without melanoma;

6) pregnancy or lactation, as well as childbearing age patients who refuse to take appropriate contraceptive measures during the trial;

7) participated in other experimental studies within 30 days before the administration of the first study drug;

8) patients not suitable for the study were judged by the researchers.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xijing Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Juliang Zhang, Prof, 029-84775271,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.